Child & Adolescent
The Recognition and Prevention (RAP) Program
Barbara Cornblatt, Ph.D., Director
| Recognition and Prevention Program (RAP) is a specialty clinic and a National Institute of Mental Health (NIMH) funded research center. The mission of the program is to prevent the development of serious mental illness in adolescents and young adults and to promote healthy functioning |
Treatment of the Schizophrenia Prodrome: Risperidone vs. Sertraline
PI: Barbara Cornblatt, PhD (516) 470-6956
Contact: Chris Smith (516) 470-6953
Comparing treatment efficacy of antipsychotic vs. antidepressant medication in treating the prodromal symptoms of psychosis.
Open Label Study of Aripiprazole in Individuals at Risk for Chronic Mental Illness
(Pharmaceutical Company Support)
PI: Barbara Cornblatt, PhD, Christoph Correll, M.D.
Contact: Chris Smith (516) 470-6953
Evaluating the Efficacy of Aripiprazole in Treating Psychosis at the Earliest Possible Stage of Presentation.
Treating Refractory Childhood Schizophrenia
(NIMH)
PI: Sanjiv Kumra, Mdcontact: Hana Kester (718) 470-8878
Study is targeted for children and adolescents with schizophrenia who have failed separate trials of olanzapine and risperidone at standard doses. This is a 12-week, random assignment, double-blind comparison of clozapine and high-dose olanzapine in 80 children and adolescents.
Treatment and Outcome of Early Onset Bipolar Disorder
(NIMH)
PI: Vivian Kafantaris, MD
Contact: Alison Berest (718) 470-8362
Treatment study of adjunctive antipsychotic medication in adolescents, ages 12 to 18, experiencing acute mania with aggressive and/or psychotic features.
Open-Label Study of Ziprasidone
(NARSAD)
PI: Sanjiv Kumra, MD
Contact: Hana Kester (718) 470-8878
Preliminary study to evaluate the effectiveness and safety of ziprasidone in children and adolescents.
Lamotrigine Add-On Study In Adolescents With Treatment Resistant Schizophrenia
(NARSAD)
PI: Sanjiv Kumra, MD
Contact: Hana Kester (718) 470-8878
Pilot study to evaluate the usefulness of lamotrigine an augmentation agent for children who are partial or non-responders to clozapine.
Oral Glucose Regulation (OGGT) in Children and Adolescents Treated With Psychotropic Medication
(NARSAD)
PI and Contact: Ema Saito, MD (718) 470-4705, Page (917) 871-0062
Study evaluates whether use of psychotropic medication results in abnormal glucose tolerance test results in obese children and adolescents.
Topiramate for Binge Eating
(Pharmaceutical Company Support)
PI and Contact: Ema Saito, MD(718) 470-4705, Page (917) 871-0062
Study evaluates whether use of topiramate decreases frequency of binge eating in adolescents.
Biological and Genetic Risk Factors for Acute Phase Novel Antipsychotic-Associated Weight Gain and Metabolic Abnormalities in Children and Adolescents
(NSLIJ Research Institute Faculty Award)
PI: Christoph Correll, MD
Contact: Tahir Mughal (718) 470-8751
This 3-month naturalistic study with an open-ended extension phase investigates the effects of novel antipsychotics on weight, lipid and glucose metabolism in children and adolescents with psychotic, mood and disruptive behavior disorders.
Molecular Mechanisms of Atypical Antipsychotic-Induced Weight Gain
(American Academy of Child and Adolescent Psychiatry)
PI: Christoph Correll, MD
Contact: Tahir Mughal (718) 470-8751
This 3-month open-label study aims at the identification of various neuropeptides that may be involved in the regulation of appetite and food intake in antipsychotic-naïve, pediatric patients undergoing treatment with olanzapine, risperidone, quetiapine or aripiprazole.
Prospective Study of Hyperprolactinemia in Children and Adolescents Treated With Atypical Antipsychotic Medication
PI and Contact: Ema Saito, MD (718) 470-4705, Page (917) 871-0062
This study evaluates whether atypical anitpsychotics cause hormonal imbalance, such as increased prolactin level, in children and adolescents. Risperidone has been found to significantly increase prolactin levels compared to olanzapine in a preliminary study.
